Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service peripheral nerve stimulation & intrathecal pumps cases in New Jersey: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 11% on average (174 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 10 | 554 | 33% |
| 2020 | 7 | 394 | 36% |
| 2021 | 8 | 522 | 39% |
| 2022 | 7 | 570 | 41% |
| 2023 | 11 | 728 | 43% |
| 2024 | 8 | 739 | 45% |
| 2025 from claims | – | 703 568–825 | 46% |
| 2026 forecast | – | 747 586–939 | 46% |
| 2027 forecast | – | 793 588–1,049 | 47% |
| 2028 forecast | – | 842 596–1,162 | 47% |
| 2029 forecast | – | 893 607–1,281 | 47% |
| 2030 forecast | – | 948 621–1,407 | 48% |
PNS lead and generator, intrathecal pump and catheter. Professional codes (what the surgeon bills): CPT 64555, 64590, 62362, 62350.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in New Jersey; 6 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 42% hospital outpatient, 55% surgery center, 3% office. The share outside the hospital has moved +20 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Hospital outpatient | Surgery center | Office |
|---|---|---|---|
| 2026 · ~750 | ~300 | ~430 | ~20 |
| 2027 · ~790 | ~310 | ~460 | ~20 |
| 2028 · ~840 | ~320 | ~500 | ~21 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: surgery center about 59% (55% in 2025), hospital outpatient about 38% (42% in 2025). More of these cases each year are decided in surgery centers, where the surgeons often own the center and weigh price and turnaround.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 22 | 1,267+7.6%/yr | +7.6%/yr | 0.6 | 39% | 2,170 in 2030+9.4%/yr |
| Pennsylvania | 15 | 1,231+6.1%/yr | +6.1%/yr | 0.8 | 44% | 1,540 in 2030+3.8%/yr |
| Massachusetts | 17 | 831+11%/yr | +11%/yr | 0.8 | 6% | 820 in 2030−0.3%/yr |
| Connecticut | 5 | 276+9.9%/yr | +9.9%/yr | 0.8 | 30% | 610 in 2030+14%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Radiofrequency ablation (facet, genicular, basivertebral) | 112 | 6,842−0.4%/yr | −0.4%/yr | 6.30.8× | 86% | 9,070 in 2030+4.8%/yr |
| Spinal cord & DRG stimulation | 12 | 392−5%/yr | −5%/yr | 0.40.9× | 70% | 450 in 2030+2.2%/yr |
Peripheral nerve stimulation & intrathecal pumps in every state, and its device makers · Every procedure market in New Jersey · Every state · Compare with New York
Spr Therapeutics leads with 52% of company spending on these surgeons in 2025, +20 pts on 2024.
In 2025, 10 companies reported engagement with New Jersey’s surgeons worth $199K in consulting, speaking, meals and travel tied to these products, about $25K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 13 clearances and approvals in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.